Sabra MM, et al. - Researchers analyzed the data to evaluate the ability of molecular targeted therapy (MTT) to influence tumor volume doubling time (TVDT) and disease-specific survival (DSS) in cases with lung metastasis from radioactive iodine-refractory progressive thyroid cancer. They recorded the median survival of 2.9 years after MTT start. They noticed a prolonged lung average tumor volume doubling time (midDT) > 3 years in 75% of cases with baseline midDT < 1 year and 100% of patients with midDT 1-3 years. In patients with rapidly progressive thyroid cancer, they found the median survival of 4.5 years in those with MTT- achieved midDT > 3 years, as compared to 2.3 years and 0.7 years in those with MTT-achieved midDT of 1-3 years and MTT-achieved midDT < 1year respectively.